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Chapter 1 
DNA and its Relationship to Cancer 
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National Hellenic Research Foundation, 48 Vas. Constantinou Ave, 
116 35 Athens, Greece. 
Abbreviations 
Deoxyribonucleic acid (DNA), 
NI : nitrogen in 1st position, 
H2A: histone 2A, 
06: oxygen in 6th position, 
Â : Angstrom, ~~ 
5': 5th position of pentose, " " — 
3': 3rd position of pentose, .— 
T: Thymine, :-
A: Adenine, 
G: Guanine, 
C: Cytosine, 
YYl:Ying-Yang-l, 
10q24: 24th position of long arm in chromosome Î0, 
JNK: c-Jun N-terminal kinase 1 (alias for MAPK8:mitogen-activated protein kinase 8), 
NF-kB: Nuclear Factor kappa B, 
PCR: polymerase chain reaction, 
c-jun: cellular homologue of jun oncogene, 
c-fos: cellular homologue of fos oncogene, 
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mRNA: messenger ribonucleic acid, 
5S: sedimentation coefficient 5, 
SRF: serum response factor, 
ATM: ataxia telangiectasia mutated, 
AP-1 : activating protein-1, 
BPDE-dG: 7r,8t - dihydroxy - 9t, 
10t - epoxy - 7,8,9,10 -tetrahydrobenzo [alpha] pyrene N2 - deoxyguanosine, 
AAF-dC: 2-acetylaminofluorene deoxycytosine, 
XP: xeroderma pigmentosum, 
XPA: xeroderma pigmentosum A, 
ERCC1: excision repair cross-complementing rodent repair deficiency complementation 
group 1, 
ROS: reactive oxygen species, 
FEN: Flap endonuclease-1, 
hOggl: human 8-oxoguanine DNA N-glycosylase, „Γ'ΓΖ^·. ~§§!r"~ 
UDG: uracil DNA glycosylase, —~"T" "" :ΞΪΓ~ 
MMR: DNA mismatch repair, 
ARF: alternate reading frame, » 
MDM2: mouse double minute 2, 
p53-binding protein; " 
oncoprotein MDM2, -^.i 
ATR: ataxia telangiectasia and Rad3-related (FRAP-related protein-1), 
DNA-PK: alias for PRKDC (protein kinase, DNA-activated, catalytic polypeptide; 
hyper-radiosensitivity of murine seid mutation, complementing 1), 
CHK2: alias for CHEK2 (CHK2 [checkpoint, S.pombe] homolog; protein kinase Chk2) 
__ DNA ^ 
Cells have two chemically similar information-carrying molecules: deoxyribonucleic 
acid (DNA) and ribonucleic acid (RNA). Both DNA and RNA in their primary structures are 
iinear polymers composed of monomers (single chemical·units) called nucleotides. DNA is 
usually double-stranded, due to formation of hydrogen bonds between units of two 
complementary strands (1). 
Each fragment of double stranded DNA that encodes for several genes and is 
individually inherited as a whole, is called a chromosome. A mammalian genome contains 
several chromosomes. Genetic information is passed on to descendant cells and organisms 
through DNA replication; DNA double strands unfold locally, to permit synthesis of 
complementary sequences by an elaborate enzymatic apparatus. During mammalian cell 
cycle, DNA is replicated in the S phase. Each daughter cell receives double stranded DNA 
that consists of one parent strand and one newly synthesized complementary strand. Each 
chromosome is represented twice in a somatic cell. This means that almost all genes are 
represented by two alleles in a mammal. Exception are the sex chromosomes χ and y. 
Chromosomes that are not associated with sex determination are the autosomes. 
DNA and its Relationship to Cancer 3 
Nucleic acid sequences that are not in a double stranded form may fold into hairpin 
structures when parts of one linear nucleic acid strand hybridize via hydrogen bonds to one 
another. Complex patterns that involve hairpins are the chromosomal telomeres of eukaryotic 
organisms in the case of DNA (1). Human chromosomes have guanine-rich sequences at the 
ends, which adopt a hairpin-folded conformation and bind specific proteins, to inhibit 
degradation. Telomerase is an enzyme which maintains chromosome length. In complete 
absence of telomerase activity chromosomes progressively shorten. This is one of the 
mechanisms which contribute to cell senescence. Cancer cells usually maintain high 
telomerase activity. 
DNA is Condensed by Complex Formation with Basic Proteins, the 
Histones 
Eukaryotic DNA is wrapped around smalTbasic proteins called histones, in a way that a 
long stretch of DNA takes up very little spaceHHistones thereby constitute half the mass of a 
eukaryotic chromosome. The entire complex of a cell's DNA and associated protein is called 
chromatin. The elementary unit of DNA and histones, is called nucleosome core particle. The 
DNA connecting core particles is termed linker DNA. Five major histones are present in 
chromatin: four histones, called H2A, H2B, H3, and H4, associate with one another; the other 
histone is called HI. A quarter of the amino acid residues in each histone are either arginine 
or lysine, giving to histones strikingly basic properties. Nucleosomes will form on almost all 
DNA sites, although some sequences are preferred because the dinucleotide steps are 
properly spaced to favor bending around the histone core. The stacked layers of nucleosomes 
form loops. This results in a very high condensation of DNA. 
The left-handed helical manner in which writhing of DNA around the histone core 
occurs, results in negative supercoils. If the nucleosomal DNA is straightened out, it will be 
underwound. This underwinding that follows nucleosome displacement, is exactly what is 
needed to separate the two DNA strands during replication, the process aimed to maintain the 
genome across cell generations and transcription, the process that initiates gene expression. 
Dynamics of Chromatin 
A typical feature of any gene is its promoter. This is a combination of specifically 
arranged DNA sequences, most often in the 5' direction from the coding sequence, that 
determine the conditions under which the gene is expressed. Catabolic genes that enable 
bacteria to survive in lactose are induced when a protein, that otherwise binds to promoter 
sequences of those genes, binds lactose and is thereby allosterically disabled from DNA 
binding. This enables expression of the catabolic genes. Eukaryotic gene regulation has 
similar features. Due to the higher complexity of eukaryotic organisms, their regulatory DNA 
sequences are more complex. Each one of the proteins that regulate gene expression 
recognizes short stretches of DNA, about 5 to 12 basepairs. Activity of such regulatory 
proteins is induced by changes in conditions, which result in alterations in the function of 
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intracellular signal transducers. Such alterations may cause covalent or structural 
modification in regulatory proteins. Modified regulatory proteins may enter the nucleus. 
While eukaryotic genome size is usually large, certain parts of it are more accessible than 
others, due to the different degree of DNA condensation. A cell type that needs a particular 
gene product more, maintains the DNA region of the corresponding gene, in a less chromatin-
condensed state. Corresponding proteins that are necessary for the induction of the 
expression ofthat gene have therefore easier access to its regulatory sequences, without being 
diluted into billions of basepairs of potential target DNA. This gene-specific differential 
degree of DNA condensation is a feature of eukaryotic cell differentiation. 
Regulation of Gene Expression at the Level of DNA Transcription is 
Strongly Dependent on DNA Sequence and is Mediated by Proteins 
A major mechanism of the control of gene expression is regulation of DNA transcription 
into RNA. It is regulated by the control of chromatin accessibility, transcription initiation, 
mRNA elongation. 
The process of DNA transcription into RNA consists of two steps: initiation, which 
requires recruitment of the template-directed enzyme RNA polymerase to the promoter of a 
given gene, and elongation, which involves the continuous addition of nucleotides to a 
growing RNA chain. In eukaryotes, RNA polymerase is recruited to a promoter by 
multiprotein complexes, many of which are common to large groups of genes. These 
complexes consist of basal transcription factors, which themselves are attracted to a promoter 
by protein-protein interactions with DNA-binding, inducible transcription factors that have 
been activated by intracellular signal cascades. Only few basal transcription factors recognize 
DNA. TATA-box binding protein recognizes the sequence TATAA or variants of it, located 
few bases upstream of transcription start sites of a very large proportion of eukaryotic genes. 
A major role in the regulation of the expression of genes is played by inducible 
transcription factors. Most inducible transcription factors recognize specific DNA sequences 
on the promoter of their target genes, and bind to them via noncovalent protein-DNA bonds. 
These transcription factors are proteins, themselves controlled in variable degrees by 
regulation of their own synthesis, posttranslational modifications, and—availability of 
mTeracliöiTpärthers (2-8). These partners modify function of transcription factors and may 
themselves access DNA indirectly, via noncovalent interaction with DNA bound 
transcription factors. Inducible transcription factors may also repress gene transcription, 
depending on the specific arrangement of target sites on a given promoter, and the species of 
factors available. The term transactivators has been used for inducible transcription factors, 
because the DNA sequences that encode the factors themselves, are most often in different 
DNA regions than the genes they regulate. They activate therefore in trans, meaning they 
activate DNA sequences neither genetically nor physically linked to the DNA sequences that 
encode the transactivators themselves. 
Inducible transcription factors bind to one or more sequences on a gene promoter, but 
their position relative to the transcription start site is not uniform for all genes that they 
regulate. An inducible transcription factor may have more than one target site on a gene 
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promoter. A given promoter has target sites for a variety of factors (1,3)· The numbers and 
relative position of those sites determines the response of the promoter to changes in the 
activity of inducible factors (8). 
Regulation of gene transcription is affected by a variety of mechanisms. Chromatin 
context and position of the gene in the nucleus affect the accessibility of the gene to the 
transcriptional apparatus (1). Availability of inducible transcription factors and signals that 
activate them determines which groups of promoters may be turned on at a given condition. 
Availability of cofactors, which do not themselves bind DNA, but modulate the activity of 
transcription factors through formation of active or inactive multiprotein complexes is also 
important. Antagonistic transcription factors may bind directly to each other preventing 
access to DNA targets or to RNA polymerase, or have overlapping DNA recognition 
sequences on the promoter of a target gene which they regulate. An example is the 
displacement of negative regulatory protein YY1 by SRF, upon SRF activation by myogenic 
signals (9). 
Further mechanisms of control of gene expression at the level of DNA transcription into 
RNA include, but are not limited to, acetylation of histones and phosphorylation of RNA 
polymerase. 
A great number of different events regulate DNA transcription into RNA (1). Events are 
integrated on the promoter of accessible genes, where a number of diverse transcription 
factors and enzymes are recruited by DNA-bound proteins. The exact combination of 
transcription factors that regulate expression of a particular gene is usually characteristic of 
the individual gene. On the other hand, genes that share certain conditions and whose 
expression is activated together, usually also share some sequence elements of their 
promoters (10). This facilitates their induction by sets and combinations of transcription 
factors that are active at the given conditions that the particular genes will be expressed 
(11,12). Proinflammatory genes, for example, share sequence elements that include 
recognition targets for factors such as AP-1 and NF-kB (2,3,13,14). 
Enzymes that activate transcription factors are themselves controlled by an immense 
variety of different signals (15). An example is the Phosphorylase JNK, which is controlled 
by changes in the intracellular oxidative environment (16), hormones (17), heat shock (18), 
upstream kinases that phosphorylate and thereby acitvate JNK itself (19), and phosphatases, 
that remove phosphate groups from JNK, deactivating it (2). JNK itself controls the activity 
of a number of diverse proteins, mostly by phosphorylation, but also by association with 
them. JNK substrates include a variety of transcription factors and other proteins that control 
gene expression (4-7). 
The most prominent substrate of JNK is the protein c-jun, a protooncogene (4). First 
identified as a cellular homologue of the 17th gene of avian myeloblastosis virus, c-jun is 
phosphorylated by JNK and activated. It forms dimers with other proteins such as c-fos, 
forming the transcription factor AP-1. AP-1 binds to DNA sequences such as the 
pseudopalindrome ATGACTCAT or variants of it. AP-1 binds to promoter DNA sequences 
of various genes such as cyclin Dl, many of which control the progression of the cell cycle 
(2,7). 
To conclude, genes are DNA sequences. Expression of genes is controlled by a variety of 
conditions that affect accessibility of DNA in the context of chromatin, DNA transcription 
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into RNA (20), splicing of the transcribed RNA, translation of the spliced RNA in the 
cytoplasm. Posttranslational modifications and stability of the gene product as well as 
interactions with other macromolecules regulate the activity of the gene product and thereby 
control the effects of the gene itself. 
Control of Gene Expression by Chromatin Remodeling 
The transcriptional regulatory mechanisms utilized by prokaryotes and eukaryotes have 
some significant differences, many of which are related to the vast difference in genome sizes 
between these classes of organisms. However, much of the DNA in a eukaryotic cell is stably 
assembled into chromatin. The packaging of DNA with chromatin renders many potential 
binding sites for transcription factors inaccessible, in effect, reducing the size of the genome 
(8). Thus, rather than scanning through the entire genome, a eukaryotic DNA-binding protein 
~~~scans a set of accessible binding sites that is close in size to the genome of a prokaryote. The 
---—cell type is determined by the genes that are accessible. 
•-'— If cell nuclei are treated with the nonspecific DNA-cleaving enzyme DNase I, cleavage is 
not uniform. DNA regions that are adjacent to actively transcribed genes are cleaved more 
efficiently than other parts of the genome. This increased accessibility of transcribed DNA to 
DNase I reflects the fact that transcribed parts of the genome are less protected (and hence 
condensed) by histones and other proteins than the rest of the DNA in a nucleus. In addition 
to the above observation, it has been noted that DNA regions of approximately 1 thousand 
base pairs (1KB) from a given transcribed (expressed) gene have an increased sensitivity to 
cleavage by nucleases such as DNase I. It has been found that nucleosomes of those regions 
have an altered conformation or are absent altogether. Such hypersensitive sites (to DNase I) 
appear when and where a given gene is actively transcribed (8), meaning in those cells that 
will activate expression of the gene, and at those specific developmental stages that will 
require the gene product to be expressed. In those tissues that the gene product will not be 
expressed, chromatin ofthat gene will remain condensed throughout development. 
When, during a study of gene regulation, a particular transcription factor is crosslinked to 
DNA in the extract of the nucleus of a eukaryotic cell and DNA is fragmented, antibodies 
—specific for the transcription factor are used to precipitate the chromatin fragments that are 
bound by the transcription factor. After breaking of the crosslinks and identification of the 
DNA fragments, usually it is observed that only a very small percentage of the factor's 
binding sites in a given genome are occupied. This technique that characterizes a factor's 
binding sites via specific antibodies that pull down the factor and its associated chromatin is 
called chromatin immunoprecipitation. Other techniques exist for the identification of a 
factor's binding sites in the nucleus of a living cell, based on cleavage of DNA within the 
nucleus, and PCR amplification of the bound fragments. The fact that only few binding sites 
are occupied by a transcription activator probably reflects the fact that with the exception of 
the genomic regions that are essential for cellular function the rest of DNA is highly 
condensed by histones in chromatin. To make this part of gene regulation clearer, it has been 
recently found that several transcription factors recruit histone-modifying enzymes to genes 
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they regulate, and other transcription factors even possess histone-modifying properties 
themselves. 
As a matter of fact, this exact modification of chromatin is a function of enhancers. Gene 
expression enhancer sequences, which may be located several thousand basepairs upstream or 
downstream from a given gene, or even within the gene itself, often serve as binding sites for 
proteins that modify chromatin regions (and sometimes interact with elements of gene 
promoters) or recruit chromatin modifiers. This property to influence chromatin 
condensation, and thereby control gene expression, makes enhancers effective at a distance 
and in a direction-independent manner. 
Swapping (exchanging) enhancers between different genes can often make the genes 
inducible under the conditions that the proteins which bind to the given enhancer are 
expressed or activated by posttranslational modification. Enhancer binding proteins are 
typical for a given cell type or a given state of cell physiology (8). Control of enhancer status 
is therefore another step whereby cell phenotype (activity of certain proteins) controls gene 
expression. i£_ ™L~ 
Control of Gene Expression by DNA Methylation 
Another level of control for gene expression is provided by DNA methylation (1,8). The 
carbon number 5 of cytosine can be methylated by some mammalian enzymes 
(methyltransferases). CpG islands, meaning DNA sequences that contain higher number of 5' 
CG 3' than the rest of the genome, are usually close to genes. This way gene expression is 
controlled: higher degree of methylation of CpG islands inhibits access of transcription 
factors (since C5 is exposed at the major groove) and thereby blocks gene expression. 
Approximately 70% of CpG islands in mammalian genomes are methylated. Deamination of 
5-methylcytosine converts it to thymine; so CpG sequences are subject to mutation to TpG. 
Natural selection and evolution have, however, maintained high density of CpG sequences 
between promoter and enhancer regions of regulated genes, to control expression. A tumor-
suppressor gene product, E-cadherin, and its undercoat proteins, catenins, which connect 
Cadherins to actin filaments, are located at lateral borders, concentrating on adherens 
_
" junctions of epithelial cells and establishing firm cell-cell adhesion. 
Cell-cell adhesion determines the polarity of cells and participates in the maintenance of 
the cell societies called tissues (8). Cell-cell adhesiveness is generally reduced in human 
cancers. Reduced intercellular adhesiveness, results in destruction of histological structure, 
which is the morphological hallmark of malignant tumors. Reduced intercellular 
adhesiveness is also indispensable for cancer invasion and metastasis. The E-cadherin cell 
adhesion system in cancer cells is inactivated by various mechanisms that reflect the 
morphological and biological characteristics of the tumor. Silencing of the E-cadherin gene 
by DNA hypermethylation around the promoter region occurs frequently, even in 
precancerous conditions. Transcriptional inactivation of E-cadherin expression was shown to 
occur frequently in tumor progression. E-cadherin expression in human cancer cells is 
regulated by CpG methylation around the promoter region. 
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Enzymes that Catalyze Conformational Changes of DNA and their 
Physiological Role 
As the two DNA strands are complementary to one another, and DNA synthesis may use 
both strands as a template for replication, resulting double strands contain one parental and 
one daughter strand (1). 
Enzymes called helicases hydrolyze ATP, opening the DNA double helix briefly for the 
replication fork to proceed. Hydrogen bonds between bases, which keep the two strands that 
form the DNA double helix together, are briefly broken. As the replication fork proceeds, 
DNA supercoil has to be locally unwound. To prevent overwinding in the regions which 
surround the replication fork, enzymes called topoisomerases introduce supercoils. Certain 
drugs that kill cancer cells are topoisomerase inhibitors (21). 
Other enzymes ensure correction of errors in DNA synthesis (21). Errors arise by 
incorporation of wrong bases in the newly synthesized DNA strands. As synthesis proceeds 
with a speed of approximately 2000 bases per second, about two wrong bases are ~ 
incorporated every second. While one daughter strand is synthesized in a continuous mode, 
the other is synthesized in a discontinuous fashion. Enzymes called ligases connect the 
fragments of this strand. As both strands of a DNA helix are copied, the replication fork 
moves along. The ends of chromosomes, however, are GC-rich linear hairpin structures. 
These are maintained by an enzyme called telomerase, which uses RNA as a template for 
DNA synthesis. It thereby belongs to the category of reverse transcriptases. 
While DNA content is almost identical for most cells of a given organism (1,8), there are _, 
several cell types that either lose their nuclear DNA (red blood cells) or undergo 
recombination (eg. antibody producing immune cells). Recombination involves cutting and 
rejoining double strands, and results in the exchange of genetic material between two parental 
strands. Cells of the germline rearrange their DNA during formation of gametes. In the 
female reproductive tract more intense recombination takes place than in the male 
reproductive tract. Another phenomenon that involves recombination is the integration of a " 
virus DNA into a host genome, and transposition, the mobilization of autonomous genetic 
elements. 
Structure of DNA within Genes 
Most Eukaryotic Genes are Split into Exons and Introns 
A basic principle of heredity is the colinearity of a gene with the gene product it codes 
for, due to the basic chemical structure of DNA that gives the genome a linear conformation 
(1). The coding region, however, of most genes of higher eukaryotes, such as birds and 
mammals, is not continuous, but rather split. It is interrupted by noncoding regions, which, 
during gene expression are transcribed together with coding regions into RNA as a whole, 
and subsequently separated from noncoding regions in the process of splicing. Lower 
eukaryotes, such as yeast, have a much higher proportion of continuous genes. In 
prokaryotes, split genes are extremely rare. The portion of a gene that is produced after 
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splicing of RNA contains sequences that direct translation of RNA into protein, and 
sequences that themselves will be translated, and code for parts of a protein. All the DNA 
regions that code for parts of the final product of splicing are termed exons. Regions of DNA 
that code for parts of RNA that are discarded after splicing are termed introns. 
DNA sequences of introns may be cut and recombined without loss of function of the 
exons that are located between introns. This fact allows for a potential mechanism of protein 
evolution via recombination between introns from different genes. 
Large sets of different proteins may be encoded by one single gene: either by initiation of 
transcription by alternative start sites, or by alternative splicing (which involves omission of 
different exons from the spliced transcript). Another way of product variation is utilization of 
alternative translation start sites from a given transcript. 
DNA Sequences within, Adjacent to, and in the Vicinity of Genes, 
Influence Gene Expression — 
As we have already encountered, promoter sequences are immediately precedent of gene 
coding sequences in the 5' to 3' direction and control the process of gene transcription. 
Enhancer sequences, which may lie within genes, or at a distance of up to several thousand 
basepairs away from genes, influence DNA transcription of genes via control of chromatin 
accessibility. 
Alterations in DNA Content May Lead to Cancer 
DNA is a relatively stable macromolecule, which stores hereditary information in living 
cells (1). Even viruses that carry RNA as genetic material, reversely transcribe RNA 
information into DNA, once they enter the reactive environment of a living cell. Inside a 
living cell, a great number of reactive molecules are present, and as RNA contains ribose, 
which has an additional hydroxyl group, it is significantly chemically less stable than DNA 
(1). DNA, therefore, being relatively stable and serving as an information storage, facilitates 
normal function and reaction of a living cell to environmental changes. As we mentioned, 
gene expression, which requires DNA transcription into RNA, is controlled by proteins (1,3). 
Concentration of certain proteins, therefore, in relation to DNA quantity of a living cell, 
determines the subsets of genes the cell will express. Changes in ploidy (chromosome 
number) and exchange of DNA between different chromosomes, as well as changes in the 
number of copies of a given gene, may alter expression of the gene(s) directly affected, and 
of many other genes, whose expression is controlled by the directly affected genes (10,22). 
Directly affected genes that have the power to cause widespread changes in gene expression 
code for transcription factors, enzymes that activate them, or intracellular and extracellular 
signal transducers, which activate such enzymes (10,22). 
Complex interplay between gene products, under influence of environment, determines 
cell phenotype (8). Result of cellular phenotypic alterations determines tissue function and 
thereby affects organism physiology. If growth signals exceed certain temporal and 
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quantitative thresholds, any normal cell will react to changes by activation of feedback 
mechanisms that control cell division. Failure of such mechanisms will activate further 
pathways of growth arrest. Cumulative failure, combined with persistent signals for cell 
division, can result in cell death. All this signal network is designed to prevent the evolution 
of cells that have uncontrolled growth. Such cells have the potential to cause cancer, and 
therefore give disadvantage to the host organism. It is easy to understand that a combination 
of defects in key control mechanisms will eventually lead to tumor formation. Due to the 
number of regulatory mechanisms, such a change is difficult to happen without an 
irreversible change in cellular DNA content (22), which allows propagation of the regulatory 
defect in daughter cells, and accumulation of regulatory changes over several cell 
generations. As the immune system surveillance has the potential to remove cancer cells, a 
signal that increases proliferation increases the potential for cancer to grow, as sheer number 
may allow some cancer cells to escape the immune system, by increasing their potential to 
accumulate regulatory changes and spread faster inside the host organism. 
Three major factors therefore contribute to cancer: changes in DNA content (21), signals 
for cell proliferation (23), and suppression of the immune system. DNA damaging agents can 
cause cancer both by increasing chances of the evolution of malignant cells, and by death of 
cells of the immune system, because as normal cells, the latter will die when subject to 
irreversible DNA damage. 
In the following paragraphs we discuss in detail the contribution of changes in DNA 
content to the evolution of cancer cells. 
Conditions that Lead to Qualitative and Quantitative Changes in DNA 
Content 
Total DNA content of a cell may be altered either by changes in chromosome number, by 
recombination between different chromosomes, by recombination between chromosomes and 
viral DNA (8,10). The DNA content of a cell may also be altered at the level of the chemical 
structure. The basic chemical structure of DNA can be altered by reactive chemicals and 
radiation. DNA damaging chemicals include several environmental carcinogens (24) and lead 
to alterations in DNA sequence, thereby affecting gene regulation or function of the gene 
product, when alterations take place within the coding sequence. 
The term carcinogen is very broad, and includes substances that have a great number of 
different effects on the basic chemical structure of DNA (21), including the formation of 
bulky aromatic-type adducts, alkylation (generally small adducts), oxidation, dimerization, 
and deamination. Chemical carcinogens may also cause epigenetic changes. A major 
epigenetic change is alteration in DNA methylation status. This type of change can lead to 
silencing of expression for specific genes. Carcinogenic DNA adducts vary in their 
mutagenic potential; the binding of benzo[a]pyrene-7,8-diol 9,10-epoxide to the exocyclic 
(N2) amino group of deoxyguanosine results in formation of an aromatic adduct that resides 
within the minor groove of the double helix, typical of polycyclic aromatic hydrocarbons. 
Although this benzo[a]pyrene-7,8-diol 9,10-epoxide adduct may turn out to be the most 
common form, by far, of DNA damage induced by benzo[a]pyrene in mammalian systems, 
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other types of DNA damage are possible, including covalent binding of metabolites to 
deoxyadenosine. Aromatic amine adducts are more complex, not only because they have both 
acetylated and nonacetylated metabolic intermediates but also because they form covalent 
bonds at the C8-, N2-, and sometimes 06-positions of deoxyguanosine as well as 
deoxyadenosine. The major adducts, however, are C8-deoxyguanosine adducts, which reside 
predominantly in the major groove of the DNA double helix. 
Sites of DNA damage caused by chemical carcinogens are acted upon by DNA repair 
enzymes (1,25-30). Six major mechanisms of DNA repair are known: direct DNA repair, 
nucleotide excision repair, base excision repair, double-strand break repair, mismatch repair, 
and postreplication repair (10). These have been characterized in lower organisms such as 
yeast and bacteria. However, among recent advances is the cloning of more than 70 human 
genes involved in five of these DNA repair pathways. 
DNA Damage Induced By Alkylating Agents and Thiopurines 
Alkylation of DNA can occur at many sites (21), either following the metabolic 
activation of certain N-nitrosamines or directly by the action of the N-alkylureas (N-methyl-
N-nitrosourea) or the N-nitrosoguanidines. The protonated alkyl-functional groups that 
become available to form lesions in DNA generally attack the following nucleophilic centers: 
adenine (Nl, N3, and N7), cytosine (N3), guanine (N2, 06, and N7), and thymine (02, N3, 
and 04). Some of these lesions are known to be repaired (06-methyldeoxyguanosine), while 
others are not (N7-methyldeoxyguanosine). Furthermore, 06-methyldeoxyguanosine is a 
promutagenic lesion, whereas N7-methyldeoxyguanosine is not. 
Direct DNA repair is carried out by DNA-alkyltransferases. These enzymes catalyze 
translocation of the alkyl moiety from an alkylated base (e.g., 06-methyldeoxyguanosine) to 
a cysteine residue at their active site, in the absence of DNA strand scission. Thus, one 
molecule of the enzyme is capable of repairing one alkyl lesion in DNA. The human 06-
methyldeoxyguanosine DNA-methyltransferase has been mapped to chromosome 10q24.33-
qter. 
Reactive Oxygen Species and 8-Oxoguanine 
Oxy-radical damage can result in the modification of DNA to form thymine glycol or 8-
hydroxydeoxyguanosine adducts. Three major pathways have been identified. Exposure to 
organic peroxides (catechol, hydroquinone, and 4-nitroquinoline-N-oxide) leads to this type 
of oxyradical damage; however, oxyradicals and hydrogen peroxide can be generated in lipid 
peroxidation and the catalytic cycling of some enzymes. Cells also can be stimulated to 
produce peroxisomes by treatment with certain drugs and plasticizers. 
The DNA base excision repair is a ubiquitous mechanism for removing damage from the 
genome induced by spontaneous chemical reaction, reactive oxygen species (ROS) and also 
DNA damage induced by a variety of environmental genotoxicants. 
Another potentially mutagenic source of DNA damage is due to the presence of 5-
methylcytosine in the genome. 5-methylcytosine transition from the methylated to the 
unmethylated state is one of the mechanisms that control gene expression, as we elaborated 
before. Mutagenic is the deamination of methylated cytosine residues in DNA. 5-
methylcytosine comprises approximately 3% of deoxynucleotides. In this case, deamination 
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at a CpG dinucleotide gives rise to a TpG mismatch. Repair of this lesion most often restores 
the CpG; however, repair may also cause a mutation (TpA). Deamination of cytosine also can 
generate a C-to-T transition, if uracil glycosylation and G-T mismatch repair are inefficient. 
Oxyradicals can enhance the rate of deamination, so the activity of inducible nitric oxide 
synthase and production of high concentrations of nitric oxide could contribute to DNA 
damage by this mechanism. 
Radiation-Induced DNA Damage 
Double-strand DNA breaks may occur from exposure to ionizing radiation and oxidation 
(31-33). Consequences of double-strand DNA breaks are the inhibition of replication past the 
break site, the inhibition of transcription of the affected gene, and the loss of heterozygosity 
in case of a gene whose other allele is defective. Double-strand DNA break repair occurs 
through homologous recombination (34), joining of the free ends is mediated by a DNA-
protein kinase in a process that also protects the ends from nucleolytic attack. The free ends Ι­
οί the DNA then undergo ligation by DNA ligase IV. Genes known to code for DNA-repair -~ 
enzymes that participate in this process include: xrcc4, xrcc5, xrccó, xrcc7, hrad51b, hrad52, 
RPA and ATM. 
Between adjacent thymine residues on the same DNA strand, ultraviolet radiation may 
induce a cyclic dimer product. 
Ways DNA Damage Causes Cancer 
DNA Damage Increases Mutation Rate 
Cell cycle control is coupled to mutagenesis: mechanisms that sense damaged DNA 
induce signals which culminate in cell cycle arrest, until damaged DNA is repaired. 
Whenever a defect causes cells to bypass this checkpoint, mutations accumulate and 
regulation of cell growth is lost. A tumor is likely to follow, and when further mechanisms 
fail, tumor cells may invade tissues and cause cancer. Mechanisms fail because loss of cell 
cycle regulation (35) and its connection with DNA repair result in higher mutation rates. 
Accessible regions of chromatin, which determine functional genes of a given cell type, 
determine also the subsets of carcinogenic mutations that will have decisive impact in the 
progression of cells toward malignancy. 
The critical cell cycle regulatory timepoint of the transition between Gl and S phases is 
controlled by a complex network of factors, some of which are ubiquitous, others appear to 
have an essential function in certain subsets of tissues. 
The majority of genes mutated in human cancers encode factors that influence the 
transition of the cell cycle from the Gl phase to the S phase, which is the phase when DNA 
replication occurs. The precocious Gl/S transition may result in an S phase deficient in 
critical regulatory factors that the cellular apparatus normally uses to ensure fidelity of DNA 
replication. Mounting problems generated due to lack of critical regulatory factors in such an 
S phase can escape detection by the cellular surveillance systems, allowing undeterred 
mitosis (21). 
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Cancer is basically thought to consist of two essential phenomena: first, tumor initiation, 
which is the point when a cell will lose control of cell cycle, and tumor promotion, when 
stimuli which cause cell proliferation will cause a significant increase in the growth of 
deregulated (initiated) cells. Cancer formation can be therefore viewed as the result from an 
imbalance between the mechanisms of cell-cycle control and mutation rates within the genes. 
Tumor initiation results from irreversible genetic damage. For mutations to accumulate, they 
must arise in cells that proliferate and survive the lifetime of the organism. A chemical 
carcinogen causes a genetic error by modification of the molecular structure of DNA that can 
lead to a mutation during DNA synthesis. Most often, this is brought about by formation of 
an adduct between the chemical carcinogen or one of its functional groups and a nucleotide 
in DNA. The number of carcinogen DNA adducts correlates with the number of tumors that 
the carcinogen causes to a susceptible animal. Tumor initiation by carcinogen adducts is due 
to activation of proto-oncogenes (conversion to oncogenes) or inactivation of tumor 
suppressor genes. _. — 
In a broad sense, genomic instability could be either manifestation of microsatellite 
instability, which exhibits a mutator phenotype, or manifestation of chromosome instability, 
which can be seen as chromosomal abnormalities at a metaphase chromosome spread. 
Nucleotide excision repair, base excision repair and mismatch repair (36) are three 
intracellular mechanisms involved in DNA damage repair that may lead to mutations. 
Nucleotide excision repair, base excision repair and mismatch repair, when they result in 
mutations, may occasionally silence a tumor suppressor gene. Inactivation of the other allele, 
even by epigenetic means such as hypermethylation of the gene promoter, may result in a 
tumor, as increased cellular proliferation has a higher chance to escape cell cycle arrest or 
coupling to the cell's own apoptotic apparatus. 
Nucleotide excision repair of DNA involves five steps: lesion recognition, preincision, 
incision, gap-filling, and ligation. Nucleotide excision repair is executed by a multiprotein 
complex consisting of 16 or more different proteins. Large distortions caused by bulky DNA 
adducts (e.g., BPDE-dG [7r, 8t-dihydroxy-9t, 10t-epoxy-7,8,9,10-tetrahydrobenzo[alpha] 
pyrene N2-deoxyguanosine] and AAF-dC [2-acetylaminofluorene deoxycytosine]) are 
recognized by specific proteins that recognize DNA damage (e.g., XPA [xeroderma 
pigmentosum A]). Removal of the DNA damage is achieved by the action of the 
endonucleases (e.g., XPF, XPG and FEN [Flap endonuclease-1]). With the intact strand 
serving as a template, a patch is constructed by 5' to 3' polymerization, and ligation of the free 
ends then takes place. Transcription-coupled DNA repair is strand specific: the transcribed 
strand in a gene is preferentially repaired by comparison to the nontranscribed or DNA 
coding strand. Nucleotide excision repair is a vital mechanism in humans and lack of this 
function results in the genetic disease xeroderma pigmentosum (XP). Markedly reduced rates 
of excision repair are found in individuals with xeroderma pigmentosum, and these 
individuals are at known risk of ultraviolet light-induced skin cancer. Based on the 
underlying genetic defect, the disease can be divided into the seven complementation groups 
XPA through XPG. XPF, in association with ERCC1, constitutes a structure-specific 
endonuclease that makes an incision 5' to the photodamage. XPF-ERCC1 has also been 
implicated in both removal of interstrand DNA cross-links and homology-mediated 
recombination. In addition to the above, XPF-ERCC1 has been implicated in a phenomenon 
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that is unrelated to DNA repair on the one hand, and very specific in respect to cell type on 
the other: immunoglobulin class switch recombination. 
Base excision repair generally removes a segment of DNA containing a small adduct: 
small adducts (e.g., 3-methyladenine) are generally the target of base excision repair so that 
there is overlap with direct repair. Removal of the adducted base is brought about by a 
glycosylase (e.g., hOggl [human 8-oxoguanine DNA N-glycosylase], UDG [uracil DNA 
glycosylase]). Repair of the damaged strand is accomplished by the combined action of an 
apurinic endonuclease (e.g., HAP1) that degrades a few bases on the damaged strand and a 
polymerase that synthesizes a patch in the 5' to 3' direction, using the undamaged strand as a 
template (e.g., polb). The patch is then ligated by one of a number of ligases (DNA ligases: I, 
II, Ilia, nib, IV). 
Excision repair processes occasionally result in DNA mismatches. DNA mismatches 
involve incorporation of unmodified or conventional, but noncomplementary, Watson-Crick 
bases opposite each other in the DNA helix. Mismatch repair process acts upon transition 
mispairs (G-T or Α-C) more efficiently than on transversion mispairs (G-G, Α-A, G-A, C-C, 
C-T, and T-T). Probable cause is differential recognition of the mispairings by the repair 
apparatus. Repair efficiency of mispairings also depends on their oligonucleotide 
environment for the same reason. Mispairings in the G-C-rich regions are therefore repaired 
more efficiently than those in the A-T-rich regions. The mechanism for the correction of 
mispairings is similar to that for nucleotide excision repair and resynthesis described earlier, 
but it generally involves the excision of large pieces of the DNA containing mispairings. 
Because the mismatch recognition protein is required to bind simultaneously the mismatch 
and an unmethylated adenine in a G-A-T-C recognition sequence, it removes the whole 
intervening DNA sequence. The parental template strand is then used by the polymerase to 
fill the gap. Relatively common mutations in hPMSl, hPMS2, hMLHl, hMSH2, hMSH3 
have been shown to predispose to human hereditary nonpoliposis colon cancer and glioma. 
DNA mismatch repair (MMR) serves to avoid replication errors and to prevent 
mutations. The association of defective MMR with familial and sporadic gastrointestinal and 
endometrial cancer has been acknowledged for some years. It has relatively recently become 
apparent that MMR defects are common in acute myeloid leukaemia/myelodysplastic 
syndrome. Acute myeloid leukaemia/myelodysplastic syndrome may follow successful 
chemotherapy for a primary malignancy. Therapy-related haematological malignancies are 
often associated with treatment with alkylating agents. Their frequency is increasing and they 
now account for at least 10% of all AML cases. There is also evidence for an association 
between MMR deficient AML/MDS and immunosuppressive treatment with thiopurine 
drugs. MMR interacts with alkylating agent and thiopurine-induced DNA damage. The 
human DNA mismatch repair (hMMR) system plays an important role in reducing mutation 
and maintaining genomic stability. The MMR system in human cells is composed of at least 
six genes (hMSH2, hMLHl, hMSH3, hPMSl, hPMS2 and GTBP/hMSH6). In particular, 
hMSH2 and hMLHl are expressed in cells undergoing rapid renewal; their reduced 
expression has been reported in several tumors. 
Specific DNA repair proteins recognize a damaged template when the apparatus of DNA 
replication encounters it. Postreplication repair will occur. One mechanism has the DNA 
polymerase stopping at the replication fork when DNA damage is detected on the parental 
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strand. Another mechanism has the DNA polymerase advancing past the lesion on the 
template, leaving a gap in the newly synthesized strand. A repair process ascribed to the 
RecA protein involves filling the gap by recombination of the homologous parent strand with 
the daughter strand. This process may lead to recombinational events. In a different repair 
process, when a single nucleotide gap remains, mammalian DNA polymerases insert an 
adenine residue. As can be expected, this process may result to base mispairing, when the gap 
involves a different residue than adenine. 
Adduct removal or unscheduled DNA synthesis is measured to define the rate of DNA 
repair. Such measurements have encountered substantial variations among individuals. An 
approximately five-fold variation in the rates of excision repair has been found in 
lymphocytes treated with carcinogens in vitro, among the general population. Markedly 
reduced rates of excision repair are found in individuals with xeroderma pigmentosum, and 
these individuals are at known risk of ultraviolet light-induced skin cancer. An association 
also has been found between the reduced capacity of mononuclear leukocytes in vitro to 
repair aromatic amine adducts in individuals who have first-degree relatives with cancer. Up 
to 40-fold variations among humans in the activity of 06-alkylguanine-DNA alkyltransferase 
have been reported as well. DNA repair rates are inhibited by aldehydes, alkylating agents, 
and some chemotherapeutic drugs. Decreased DNA repair capacity also has been noted in the 
fibroblasts of patients with lung cancer, compared with those patients with melanoma or 
noncancer controls. For benzo[a]pyrene-7,8-diol 9,10-epoxideDNA adducts, a unimodal 
distribution of repair rates is observed in lymphocytes, but interindividual variation has been 
found to be substantial. 
As ultraviolet radiation can initiate carcinogenesis by means of mutation, it can also 
supply tumor promotion by activating cell division. Phosphatases can get inactivated by UV, 
allowing for prolonged activation of kinase enzymes such as JNK, which activates some 
transcription factors which turn on cyclin D gene expression and thereby facilitate Gl/S 
transition. 
DNA Damage Kills Immune Cells 
Mutagenic agents may also lead to cancer formatiorrvia suppression of the immune 
system, which normally can remove defective cells before the formation of large tumors. 
Mechanisms which kill cells that accumulate mutations, may cause also widespread death of 
immune cells, and leave an organism unprotected from cancer. This is evident in nude mice, 
which are highly susceptible to tumors (21,22). 
We can view an example of a successful strategy for confrontation with tumors in the 
case of skin cancer. Knowledge of both aforementioned pathways of carcinogenesis is 
applied to inhibit cancer formation. 
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How is Knowledge of Cancer Development Due to DNA Damage Applied: 
Two Anticancer Compounds, Imiquimod and Dimenane 
The example of skin cancer prevention and treatment illustrates well two major 
mechanisms of carcinogenesis. The drug imiquimod, originally prescribed for genital warts, 
is an effective activator of the immune system of the skin. As sun rays damage a variety of 
cell types on the skin, imiquimod prevents development of malignancy by activating the 
immune system which kills tumor cells. Another drug, dimericin, contains an enzyme that 
breaks thymine dimers, the cyclic product of the sun's ultraviolet radiation on DNA. 
Dimericin prevents mutations, thereby inhibiting one major factor of sun-induced 
carcinogenesis. 
Gene Aberrations that Lead to Cancer: Generation 
of Oncogenes and Inactivation of Tumor -
Suppressor Genes 
If alterations in DNA cause cancer, then how does it happen? Deregulation of the cell 
cycle may happen either by activation of oncogenes, which activate cell growth, or by 
inactivation of tumor suppressor genes, which cause cell cycle arrest or death (10,21,22). 
Oncogenes are generated by changes in the structure or function of normal cellular genes 
called protooncogenes. 
Normal Function of Protooncogenes 
Protooncogenes are genes which under conditions of overexpression or uncontrolled 
activity lead to cancer. Protooncogenes usually code for proteins which naturally function as 
stimulus-responsive switches towards cell proliferation. 
Conversion into Oncogenes 
A protooncogene may be converted to an oncogene by mutations that alter the levels of 
expression of the gene product, or by mutations which alter the function of the gene product, 
abrogating certain restrictions on the activity. 
A classic case of a known conversion of a gene into an oncogene is the Finkel Biskis 
Jinkins murine osteosarcoma gene. The corresponding virus carries this oncogene, which has 
a cellular counterpart termed c-fos. Another case is the avian myeloblastosis virus gene 17, 
termed v-jun (from junana, Japanese word meaning 17). Its cellular counterpart, c-jun, codes 
for a protein that forms heterodimers with c-fos protein. These two gene products are 
expressed rapidly in response to a number of stimuli, and c-jun is posttranslationally modified 
by phosphorylation which activates it. c-jun heterodimers with c-fos, or c-jun homodimers, 
may bind to promoters of target genes, as constituents of the transcription factor AP-1 (4-7). 
AP-1 target sequences are present on the promoter DNA of many genes that are expressed in 
response to inflammation and a variety of other conditions. AP-1 target genes modulate the 
cell cycle and influence phenomena related to the development of malignancy. 
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Substrates of Protooncogenes (and Oncogenes) 
Protooncogenes generally code for various signal transducers which transmit signals that 
activate cell division. 
Some protooncogenes code for enzymes that in response to a number of stimuli activate 
cell growth. 
Other protooncogenes code for transcription factors which in response to 
phosphorylation by growth-stimulus responsive enzymes activate expression of genes which 
are involved in cell cycle progression and immortalization. 
Activators of Protooncogenes 
Natural activators of protooncogenes include mitogenic stimuli and downstream effectors 
thereof. Several protooncogenes serve also as signal pathway components for processes not 
directly related to cell growth, such as inflammatory events (secretion of cytokines, adhesion 
factors). 
Effects of Protooncogenes on Cell Fate 
Activated protooncogenes may contribute to inhibition of cell death and activation of cell 
proliferation. Aberrantly activated protooncogenes, as is the case by tumor promoters, may 
thereby contribute to cancer without a mutation on the gene itself. Effects of activated 
protooncogenes include cell cycle progression beyond checkpoints, relief of repair 
requirement, loss of attachment, immortality, tissue invasion, and competition of cancer 
growth against detection and destruction by the immune system. 
Definition of Tumor Suppressor Genes 
As tumor suppressor genes are termed genes whose loss of both copies of a cell is 
associated with acquisition of the malignant phenotype. 
Inactivation of Tumor Suppressors in Cancer 
In cancer, tumor suppressor genes are either inactivated, or the signal networks through 
which they control cell growth are disabled. Familial cancer syndromes are usually marked 
by a defect in one copy of a tumor suppressor gene. In somatic cells the other copy may be 
inactivated either by mutagenic (genotoxic) conditions or by methylation. Absence of both 
copies of a tumor suppressor gene is conducive to irregular growth of the cell. 
Normal Function of Tumor Suppressor Genes 
Tumor suppressor genes may be activated by deregulated cell cycle progression and 
cause cell cycle arrest, cell death, or both. Alternatively, tumor suppressor genes may ensure 
genomic stability. 
Tumor suppressor gene products are proteins that may halt cell cycle, when a cell has 
acquired irreversible changes that lead to malignancy, or may work to prevent such 
irreversible changes. 
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Specific Examples 
p53, Rb, BRCA1 are tumor suppressor genes (21,37-41). The function of each one is 
unique, even though they belong to families of genes with partially overlapping functions. A 
different category of tumor suppressor genes, includes those that code for proteins involved 
in specific downstream effects of DNA repair, such as XPA. Those genes have not yet been 
strongly implicated in core functions of intracellular signal pathways. Mutations in DNA 
repair genes serve mainly to increase the frequency of tumor initiation, while mutations in 
genes that regulate the cell cycle result in tumor promotion. 
p53 
p53 is a well known gene, and has several homologues. There may be a certain degree of 
partial redundancy between p53 and its homologues termed p73 and p63 (42). 
p53 is a gene with many functions. It codes for a protein that is able to repress or activate 
transcription, depending on the circumstances and the genes observed. From all genes that 
play a role in the regulation of programmed cell death, p53 has been the most intensively 
studied. Potential p53 effects include activation of cell cycle arrest, senescence, and 
differentiation. Most research until now has been focused on the role of p53 in apoptosis of 
senescent or stressed cells. 
p53 itself is positively regulated by the gene ARF and negatively regulated by MDM2. 
Mice without ARF (ARF knockout mice) develop tumors at a very fast pace. MDM2, on the 
other hand targets p53 for ubiquitination (and subsequent degradation). p53 activates 
transcription of MDM2. This way, in the absence of an apoptotic stimulus, p53 levels are 
kept low. Activation of p53 in response to cellular stress such as DNA damage, oncogene 
activation, telomere erosion and hypoxia is mediated, at least in part, by inhibition of MDM2 
and rapid stabilization of the p53 protein. 
Although DNA transcription-independent effects of p53 have been described, the best 
understood function of p53 is that of a transcription factor (38,43) for genes that mediate 
DNA damage repair, growth arrest and apoptosis (39-41). Mice or embryonic stem cells in 
which p53 wild-type protein was substituted by a transcriptionally inactive mutant lost cell 
cycle arrest and apoptotic functions. On the other hand, the ability of p53 to repress 
transcription might well explain some of its effects, particularly the induction of apoptosis. 
The mechanisms and requirements for p53-mediated transcriptional repression are under 
intense study. 
Cell cycle arrest by p53 can be explained by the transcriptional activation of the 
p21WAFl/CIPl cyclin-dependent kinase inhibitor. Apoptosis, on the other hand, does not 
appear to involve one single mechanism. Notably, transformed cells have a greater difficulty 
to recover from cell cycle arrest than primary cells. Some normal cells (e.g., normal gut 
epithelium and hematopoietic), however, cannot recover from cell cycle arrest and undergo 
p53-induced death. Selective inhibition of p53 in such tissues might alleviate some side 
effects of chemotherapy. Conversely, reactivation of p53 may be used as a way to sensitize 
some resistant cancer cells to radiation or chemotherapy. 
18 different sites in human p53 are reported to be posttranslationally modified. Most are 
modified in response to genotoxic stress. p53 is modified in three different ways: by 
phosphorylation, by acetylation, and by sumoylation. Key sites appear to be targeted by more 
than one signaling enzyme, and there is growing evidence that modifications to several sites 
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are linked in cascades that may provide signal amplification and integration. One example of 
p53 regulation is provided by the enzyme JNK (2,37,38). JNK, when inactive, binds to p53 
between residues 97 and 116 and targets p53 for proteasomal degradation. When JNK is 
activated by apoptotic stimuli, it phosphorylates p53 at residue threonine 81 and thereby 
activates it. It is important to note here that JNK and p53 apoptotic pathways do not overlap 
extensively. Multiple different pathways for p53 activation exist, and conversely, JNK has 
multiple proapoptotic substrates. Epigenetic studies have shown that mutating or inactivating 
putative or established 'tumor-suppressor' proteins that play a role in the DNA damage 
response, including ATM, ATR, DNA-PK, CHK2, breast-cancer-susceptibility gene-1 
(BRCA1) or PKR, can prevent or attenuate the activation of p53 by DNA damage. Key 
perturbations that are thought to lead to p53 activation include the production of oxidant 
radicals (i.e. oxidative stress), damaged DNA structures or repair intermediates, and the 
inhibition of enzymes that affect RNA polymerase II-dependent transcription. 
p53 is also essential for the senescence response to a variety of signaling factors. 
Senescence might have evolved to suppress tumor development. p53 may initiate the 
senescence response partly through the induction of p21. 
Activity at of Tumor Suppressor Genes at Cell Cycle Checkpoints 
An entirely different tumor suppressor gene from p53 can be illustrated in the case of 
BRCA1; germline mutations of this gene are known to confer susceptibility to breast and 
ovarian cancer in high-risk families (21). BRCA1 as a tumor suppressor plays an important 
role in maintaining genomic stability. BRCA1 has the ability to interact with numerous 
proteins and to form complexes that are involved in recognizing and subsequently repairing 
DNA. BRCA1 contains several functional domains that directly or indirectly interact with a 
variety of proteins via protein-protein interaction; these include tumor suppressors (BRCA2, 
p53, Rb and ATM), oncogenes (c-Myc, casein kinase II and E2F), DNA damage repair 
proteins (RAD50 and RAD51), cell cycle regulators (cyclins and cyclin dependent kinases), 
transcriptional activators and repressors (RNA polymerase II, RHA, histone deacetylase 
complex and CtIP), DNA damage-sensing complex and mismatch repair proteins (BRCA1-
Associated Surveillance Complex; BASC) and signal transducer and activator of 
transcription (STAT) among others. Throughout the cell cycle BRCA1_ protects genomic 
DNA. Further effects of BRCA1 include control of the fidelity of DNA replication (to 
prevent mutations that would be passed on to daughter cells) and control of the separation of 
sister chromatids during mitosis (to prevent unequal distribution of genetic information to 
daughter cells). Gene knockout and overexpression models indicate that BRCA1 is an 
integral component of both of these checkpoints. Elimination of BRCA1 from the mouse 
genome results in early embryo death at day 78. On the other hand, overexpression of 
BRCA1 causes cell cycle arrest. 
Cell cycle arrest caused by overexpression of BRCA1 requires the presence of p21WAFl 
or protein Rb, both proteins that are involved in the Gl/S checkpoint. In the case of the Gl/S 
checkpoint, BRCA1 is (in contrast to p53) not required to halt the cell cycle in the case of 
damage. BRCA1 is apparently necessary for proper repair of damage that may occur during 
or prior to S phase. Human cancers caused by mutation of BRCA1 may be due to 
accumulation of mutations in somatic cells that result in a cascade of events which culminate 
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in uncontrolled cell proliferation. Formation of foci containing BRCAl by inherited 
mutations, or epigenetic mechanisms (promoter methylation) in sporadic cancers leads to a 
loss of DNA repair ability, disrupts the potential to form complexes with other proteins that 
are crucial for DNA repair pathways. Thus, BRCAl plays a significant role in maintaining 
genomic stability and serves as a tumor suppressor in breast cancer tumorigenesis. 
Almost exclusive for developing embryos, albeit to a much lower level than full length, a 
truncated form of BRCAl, lacking the exon 11, is expressed in cells. A transgenic mouse that 
only expressed this truncated form of BRCAl gave embryo fibroblasts that senesced much 
faster than wild-type cells and harbored a plethora of genomic abnormalities. Observed 
chromosomal alterations could be the result of unequal recombination and breakage, two 
anomalies that predominantly occur during mitosis. Indeed, these fibroblasts treated with 
DNA damaging agents failed to enact their G2/M checkpoint, and progressed into mitosis as 
if there was no chromosomal damage. A possible cause for this increase of chromosomal 
breakage may be the amplification of centrosomes in mitotic cells. Centrosomes are a prime 
location for BRCAl during mitosis. Pulling on chromatids in several directions as opposed to 
just the polar ends of the dividing cell could certainly have an effect on the state of the 
chromosomes after anaphase. Lack of full length protein at these complexes could account 
for the amplification. The overall lack of G2/M checkpoint control pointed clearly at the 
involvement of the exon 11 region of BRCAl as an essential factor in qualifying cells for 
division. Overexpression of the C-terminus of BRCAl in normal breast epithelial cells has 
also been shown to adversely affect G2/M checkpoint control. 
Rb 
The tumor suppressor gene Rb (21) is an important component in the G(l)/S transition 
and its function is abnormal in most human neoplasms. The RB gene family includes three 
members: Rb/pl05, pl07 and RB2/pl30. The regulation of all three members of the 
retinoblastoma family of proteins is complex and unique for each single member. Each 
member of the RB family of growth suppressive nuclear phosphoproteins elicits Gl growth 
arrest upon ectopic expression in sensitive cell lines, and their phosphorylation status is 
regulated in a cell cycle-dependent manner. 
The retinoblastoma protein (RB) plays a key role in the control of cell proliferation and 
mediates the terminal differentiation of certain cell types. Increasing evidence suggests that 
RB functions by contacting and modifying the behaviour of transcription factors. RB can 
form complexes with E2F and MyoD in vivo, and complexes with a number of other 
transcription factors have also been demonstrated in vitro. Following DNA damage, the p53-
dependent induction of p21CIPl regulates cyclin E/Cdk2 and cyclin A/Cdk2 complexes both 
of which phosphorylate pRB, leading to E2F-mediated activation. 
Another effect of Rb concerns RNA polymerase III. RNA polymerase (pol) III 
synthesizes a range of essential products, including tRNA, 5S rRNA and 7SL RNA, which 
are required for protein synthesis and trafficking. High rates of pol ΠΙ transcription are 
necessary for cells to sustain growth. A wide range of transformed and tumour cell types have 
been shown to express elevated levels of pol III products. Some transforming agents have 
been shown to stimulate expression of the pol Ill-specific transcription factors TFIIIB or 
TFIIIC2. In addition, TFIIIB is bound and activated by several oncogenic proteins, including 
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c-Myc. Conversely, TFIIIB interacts in healthy cells with the tumour suppressors RB and 
p53. Indeed, the ability to limit pol III transcription through TFIIIB may contribute to their 
growth-suppression capacities. The function of p53 and/or RB is compromised in most if not 
all transformed cells. 
Progress in molecular biology leads to a growing picture of the interaction network 
between different tumor suppressor genes. Currently p53 and Rb may be the best studied. 
pRB and p53 are involved in the regulation of the Gl/S transition and its checkpoints, to a 
large extent under the control of the E2F transcription factor family. Following DNA 
damage, the p53-dependent induction of p21CIPl regulates cyclin E/Cdk2 and cyclin 
A/Cdk2 complexes both of which phosphorylate pRB, leading to E2F-mediated activation. 
Similarly, E2F1-dependent induction of pl9ARF antagonizes the ability of mdm2 to degrade 
p53, leading to p53 stabilization and potentially p53-mediated apoptosis or cell cycle arrest. 
From the existing mouse models discussed above, we also know that proliferation, cell death 
and differentiation of distinct tissues are also intimately linked through entrance and exit 
from the cell cycle, and thus through pRB and p53 pathways. Virtually all human tumors 
deregulate either the pRB or p53 pathway, and often times both pathways simultaneously, 
which is critical for crippling cellular defence against neoplasia. 
Oncogenes, Tumor Suppressor Genes and Aging 
Mammalian aging is partly due to a decline in the restorative capacity of tissue stem 
cells. Stem/progenitor cells ensure tissue and organism homeostasis and might represent a 
frequent target of transformation. Although these cells are potentially immortal, their life 
span is restrained by signalling pathways (pl9-p53 and pl6-Rb) that are activated by DNA 
damage (telomere dysfunction, environmental stresses) and lead to senescence or apoptosis. 
Tissue stem cells are rendered malignant by a small number of oncogenic mutations. 
Overlapping tumor suppressor mechanisms (e.g., pl6(INK4a)-Rb, ARF-p53, and the 
telomere) have evolved to ward against this possibility. Execution of these antitumor 
checkpoint pathway programs, however, appears to limit the stem cell life span, and may 
thereby lead to stem cell depletion. Stem cell depletion can result to organism aging. 
DNA Manipulation 
At least 2 principal ways of DNA manipulation are available (1,8). The one relies on 
purified enzymes or chemistry and involves assembly or modification of DNA sequences in 
vitro (in the test tube). The other is expressing DNA-modifying enzymes inside living cells. 
DNA modifying enzymes, are expressed under the control of tissue-specific or inducible 
promoters, and can carry out the same functions that they perform in a test tube. Expressing 
them into a living cell allows study of the effects that modification of the genome inside a 
living organism has. A specific gene, for example can be knocked out in selected tissues of a 
transgenic animal. 
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In vitro synthesis of DNA can be carried out using template-driven DNA polymerase 
enzymes which make copies of an existing DNA sequence. DNA can be cut using nucleases, 
which selectively cut either double-stranded or single-stranded nucleic acid. Exonucleases 
degrade nucleic acids starting from ends, while endonucleases cleave within the strand. A 
powerful tool for biology emerged with the discovery of sequence-specific endonucleases, 
which normally are utilized by bacteria to degrade (restrict) foreign DNA. Sequence-specific 
endonucleases recognize specific DNA target-sites and cut DNA within the site or at a given 
distance from it. Some restriction endonucleases cut double stranded DNA in an asymmetric 
fashion, leaving overhanging ends of few bases. 
Within a certain range from neutral pH, DNA has a negative charge, therefore cleaved 
DNA strands are separated by electrophoresis in agarose gels, and visualized by staining with 
dyes (e.g. ethidium bromide) which intercalate between the stacked base pairs. 
End-modifying enzymes exist, that allow adapting ends of synthesized or cleaved DNA 
fragments to become substrates for further manipulation. Such manipulation may be carried 
out by ligases, which may join ends of DNA fragments. Overhanging ends of cleaved DNA 
may also be filled-in using enzymes such as bacterial DNA polymerase I. Such a reaction 
allows labeling a DNA fragment using incorporation of radioactively labeled nucleotides, 
usually carrying phosphor isotopes. 
Aims of DNA Manipulation 
Aims of DNA manipulation include, but are not limited to, study of the properties of 
gene products (1,8), generation of proteins with altered properties and study of biophysical 
aspects of macromolecular interactions (DNA-protein, DNA-RNA, etc). 
Mutational Dissection Allows for Study of Gene Products 
A number of different parts of any given protein can be modified via modification of the 
gene that codes for it. Through recombinant DNA technology a gene is modified via the 
change of one or more amino acid encoding triplets. Any part of a gene can be removed or 
exchanged with parts from another gene. Such work has as result the generation of a 
correspondingly modified gené^product. This facilitates research into the activities" of gene 
products. Proteins that arise from gene manipulation are highly informative and provide great 
insight into the function of the gene, because recombinant DNA can be introduced into 
virtually any organism, allowing a dissection of their function. A gene of an organism can 
also be manipulated or deleted from the host genome. Lack of the gene, results in an 
organism deprived of a great part of its function, with the exception of cases that products of 
other genes are activated to replenish partially or completely the functions of the deleted 
gene. Input from disease models is also used for gene characterization and analysis, and gives 
first indications of the role of genes. Gene manipulation and further study of introduced 
mutations in experimental models helps characterize the role of gene products in cell 
physiology, and in the case of cancer, regulation of cell growth. 
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mRNA Can be Reverse-Transcribed into Cdna, Giving Information on 
Expressed Genes 
To clone a gene that is expressed in a mammalian cell, we isolate the RNA that is 
contained in the cell. RNA includes mRNA, which is the intermediate of gene expression. 
Through precipitation using polyT sequences (which hybridize the polyA tails of mRNA) one 
can enrich for mRNA. Then, using the enzyme reverse transcriptase (isolated from 
retroviruses and commercially available), the mRNA is reverse transcribed into DNA, called 
cDNA (copyDNA), using polyT primers. 
Enzymes That are Utilized to Produce and Propagate Recombinant DNA 
The discipline of manipulation of genes through planned DNA sequence modifications is 
called recombinant DNA technology. The basis of recombinant DNA technology relies on 
the ability to manipulate DNA molecules in the test tube. This ability for planned DNA 
manipulation involves utilization of purified enzymes whose activities and substrates are 
characterized and can be controlled. Purified enzymes can therefore be used to make 
specified changes to the DNA molecules that are being manipulated. The enzymes available 
to the molecular biologist mostly originate from bacteria which possess certain identified 
properties, and can be classified into four broad categories: 
DNA polymerases, enzymes that synthesize new polynucleotides complementary to an 
existing DNA or RNA template. 
Nucleases, which degrade DNA molecules by breaking the phosphodiester bonds that 
link one deoxynucleotide to the next. 
Ligases, which join DNA molecules by synthesizing phosphodiester bonds between 
deoxynucleotides at the ends of two different molecules, or at the two ends of a single 
molecule. 
End-modification enzymes, which make changes to the ends of DNA molecules, adding 
an important dimension to the design of ligation experiments, and providing one means of 
labelling DNA molecules with radioactive and other markers. 
Results of DNA Manipulation 
While mostly used to study genes through the analysis of the properties of their products, 
recombinant DNA technology has other aims as well. It is used to develop novel treatments 
for incurable diseases and to address problems of crops and livestock: recombinant proteins 
that arise from expression of genes with modified DNA are used to convey altered properties 
to genetically modified organisms, with desirable results and sometimes undesirable side 
effects. 
Progress in recombinant DNA technology has allowed the characterization of the human 
genome and promises to have an important part to contribute to characterization of the far 
more complex proteome. 
24 Spiros Vlachopoulos and Vassilis Zoumpourlis 
Perspectives from DNA Manipulation 
Advances in therapeutic strategies aimed to cure currently untreatable syndromes are 
expected to arise from the application of recombinant DNA technology (44). 
Chemotherapeutic drugs for cancer treatment have been traditionally originated by the 
isolation of natural products from different environmental niches, by chemical synthesis or by 
a combination of both approaches thus generating semisynthetic drugs. Genetic manipulation 
of antitumor biosynthetic pathways may offer an alternative in the near future. Novel 
antitumor derivatives have been generated by targeted gene disruption and heterologous 
expression of one or few genes in another host, and also by combination of genes that code 
for components of different, but structurally related biosynthetic pathways. 
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